Efficacy of Two-Weekly Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy for Breast Cancer

Nanomedicine (Lond). 2019 Jun;14(12):1595-1603. doi: 10.2217/nnm-2018-0485. Epub 2019 Apr 12.

Abstract

Aim: Compare the two-weekly regimens of nanoparticle albumin-bound paclitaxel (nab-P) with solvent-based paclitaxel (sb-P) as neoadjuvant chemotherapy for breast cancer. Materials & methods: Patients (n = 162) with operable early breast cancer received four cycles of dose-dense epirubicin and cyclophosphamide followed by four two-weekly cycles of nab-P (n = 83) or sb-P (n = 79), with trastuzumab when needed. Results: Across all the patients, the ypT0 ypN0 and ypT0/is ypN0 pathological complete response rates in the nab-P group were not superior to those in the sb-P group. However, pathological complete response rates for triple-negative breast cancer were significantly better with nab-P than with sb-P. Meanwhile, nab-P also induced more peripheral sensory neuropathy. Conclusion: The two-weekly nab-P regimen is a good neoadjuvant chemotherapy choice for triple-negative breast cancer.

Keywords: breast cancer; nanoparticle albumin-bound paclitaxel; neoadjuvant chemotherapy; pathological complete response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Albumin-Bound Paclitaxel / chemistry*
  • Albumin-Bound Paclitaxel / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Cyclophosphamide / therapeutic use
  • Epirubicin / therapeutic use
  • Female
  • Humans
  • Middle Aged
  • Nanoparticles / chemistry*
  • Neoadjuvant Therapy / methods
  • Retrospective Studies
  • Trastuzumab / therapeutic use

Substances

  • Albumin-Bound Paclitaxel
  • Epirubicin
  • Cyclophosphamide
  • Trastuzumab